Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christophe Almeras

Showing results (41-50 of 52) with videos related to

Pageof 6
Sort By:
Urologic Oncology|April 22, 2020
Intercenter reproducibility of software-based fusion biopsies for grade group prediction when targeting suspicious MRI lesionsCécile Manceau, Mathieu Roumiguié, Marine Lesourd, et al.
Urology|January 4, 2020
Impact of MRI and Targeted Biopsies on Eligibility and Disease Reclassification in MRI-positive Candidates for Active Surveillance on Systematic BiopsiesGuillaume Ploussard, Jean-Baptiste Beauval, Marine Lesourd, et al.
World Journal of Urology|June 15, 2019
Performance of systematic, MRI-targeted biopsies alone or in combination for the prediction of unfavourable disease in MRI-positive low-risk prostate cancer patients eligible for active surveillanceGuillaume Ploussard, Jean-Baptiste Beauval, Marine Lesourd, et al.
The Journal of Urology|June 28, 2019
Added Value of Concomitant Systematic and Fusion Targeted Biopsies for Grade Group Prediction Based on Radical Prostatectomy Final Pathology on Positive Magnetic Resonance ImagingGuillaume Ploussard, Jean-Baptiste Beauval, Marine Lesourd, et al.
World Journal of Urology|October 16, 2019
Active surveillance eligibility of MRI-positive patients with grade group 2 prostate cancer: a pathological studyGuillaume Ploussard, Jean-Baptiste Beauval, Marine Lesourd, et al.
Journal of Clinical Medicine|January 19, 2020
Assessment of the Minimal Targeted Biopsy Core Number per MRI Lesion for Improving Prostate Cancer Grading PredictionGuillaume Ploussard, Jean-Baptiste Beauval, Raphaële Renard-Penna, et al.
European Urology Oncology|February 25, 2024
Transperineal Versus Transrectal Magnetic Resonance Imaging-targeted Biopsies for Prostate Cancer Diagnosis: Final Results of the Randomized PERFECT trial (CCAFU-PR1)Guillaume Ploussard, Eric Barret, Gaëlle Fiard, et al.
World Journal of Urology|February 20, 2021
The prognostic value of high-grade prostate cancer pattern on MRI-targeted biopsies: predictors for downgrading and importance of concomitant systematic biopsiesCécile Manceau, Gaëlle Fromont-Hankard, Jean-Baptiste Beauval, et al.
Journal of Clinical Medicine|June 27, 2020
Survival Outcomes of Patients with Pathologically Proven Positive Lymph Nodes at Time of Radical Cystectomy with or without Neoadjuvant ChemotherapyGuillaume Ploussard, Benjamin Pradere, Jean-Baptiste Beauval, et al.
The French Journal of Urology|March 14, 2025
Communication and diffusion of the 2022 French Urolithiasis Guidelines (CLAFU): Lessons from a national auditStessy Kutchukian, Marie Chicaud, Nadia Abid, et al.
Pageof 6

Showing results (41-50 of 52) with videos related to

Sort By:
Pageof 6
Urologic Oncology|April 22, 2020
Intercenter reproducibility of software-based fusion biopsies for grade group prediction when targeting suspicious MRI lesionsCécile Manceau, Mathieu Roumiguié, Marine Lesourd, et al.
Urology|January 4, 2020
Impact of MRI and Targeted Biopsies on Eligibility and Disease Reclassification in MRI-positive Candidates for Active Surveillance on Systematic BiopsiesGuillaume Ploussard, Jean-Baptiste Beauval, Marine Lesourd, et al.
World Journal of Urology|June 15, 2019
Performance of systematic, MRI-targeted biopsies alone or in combination for the prediction of unfavourable disease in MRI-positive low-risk prostate cancer patients eligible for active surveillanceGuillaume Ploussard, Jean-Baptiste Beauval, Marine Lesourd, et al.
The Journal of Urology|June 28, 2019
Added Value of Concomitant Systematic and Fusion Targeted Biopsies for Grade Group Prediction Based on Radical Prostatectomy Final Pathology on Positive Magnetic Resonance ImagingGuillaume Ploussard, Jean-Baptiste Beauval, Marine Lesourd, et al.
World Journal of Urology|October 16, 2019
Active surveillance eligibility of MRI-positive patients with grade group 2 prostate cancer: a pathological studyGuillaume Ploussard, Jean-Baptiste Beauval, Marine Lesourd, et al.
Journal of Clinical Medicine|January 19, 2020
Assessment of the Minimal Targeted Biopsy Core Number per MRI Lesion for Improving Prostate Cancer Grading PredictionGuillaume Ploussard, Jean-Baptiste Beauval, Raphaële Renard-Penna, et al.
European Urology Oncology|February 25, 2024
Transperineal Versus Transrectal Magnetic Resonance Imaging-targeted Biopsies for Prostate Cancer Diagnosis: Final Results of the Randomized PERFECT trial (CCAFU-PR1)Guillaume Ploussard, Eric Barret, Gaëlle Fiard, et al.
World Journal of Urology|February 20, 2021
The prognostic value of high-grade prostate cancer pattern on MRI-targeted biopsies: predictors for downgrading and importance of concomitant systematic biopsiesCécile Manceau, Gaëlle Fromont-Hankard, Jean-Baptiste Beauval, et al.
Journal of Clinical Medicine|June 27, 2020
Survival Outcomes of Patients with Pathologically Proven Positive Lymph Nodes at Time of Radical Cystectomy with or without Neoadjuvant ChemotherapyGuillaume Ploussard, Benjamin Pradere, Jean-Baptiste Beauval, et al.
The French Journal of Urology|March 14, 2025
Communication and diffusion of the 2022 French Urolithiasis Guidelines (CLAFU): Lessons from a national auditStessy Kutchukian, Marie Chicaud, Nadia Abid, et al.
Pageof 6